Qinlock

Approved Uses

Qinlock is used to treat a specific type of cancer called advanced gastrointestinal stromal tumor (GIST). It is intended for adults who have already been treated with three or more other kinase inhibitor medications.

GIST is a type of cancer that develops in the tissues of the gastrointestinal tract, most commonly in the stomach or the small intestine. Qinlock is typically prescribed when the cancer has spread to other parts of the body or cannot be removed by surgery.

Treatment Context

This medication is considered a fourth-line treatment, meaning it is used after other standard therapies have been tried. It is specifically for patients who have previously received treatment with the following medications:

• Imatinib
• Sunitinib
• Regorafenib

Mechanism of Action

Qinlock belongs to a class of medications known as kinase inhibitors. It is specifically designed to treat gastrointestinal stromal tumors (GIST) by targeting the underlying causes of cell growth.

Targeting Cancer Proteins

The medication works by interfering with the action of two specific proteins:

• KIT
• PDGFRA

In many cases of GIST, these proteins are mutated, causing them to stay in an "on" position. This sends continuous signals to cancer cells, telling them to divide and spread throughout the body.

Slowing Tumor Growth

Qinlock acts as a switch-control inhibitor. It binds to these proteins and blocks the signals they send. By inhibiting these pathways, the drug helps to:

• Slow the growth of existing tumor cells.
• Prevent the spread of the cancer to other parts of the body.
• Target mutations that may have become resistant to other kinase inhibitor treatments.

Common Side Effects

Many people taking Qinlock experience mild to moderate side effects. These may include:

• Hair thinning or hair loss
• Feeling very tired or weak (fatigue)
• Nausea or vomiting
• Stomach pain, constipation, or diarrhea
• Muscle or joint pain
• Decreased appetite and weight loss
• Headache
• Hand-foot syndrome (redness, pain, swelling, or blisters on the palms of the hands or soles of the feet)

Serious Side Effects

While less common, Qinlock can cause serious health problems. Contact your healthcare provider immediately if you notice:

• New skin changes: This includes new warts, skin sores, or reddish bumps that bleed or do not heal, as Qinlock may increase the risk of certain skin cancers.
• Heart problems: Symptoms such as shortness of breath, palpitations, or swelling in the ankles and feet.
• High blood pressure: Your doctor should monitor your blood pressure regularly during treatment.
• Wound healing issues: Qinlock can interfere with how your body heals after surgery.

This is not a complete list of side effects. Always report new or worsening symptoms to your medical team.

Skin Reactions

A common side effect is palmar-plantar erythrodysesthesia, also known as hand-foot syndrome. This condition causes redness, pain, swelling, or blisters on the palms of the hands and soles of the feet. Some patients may also experience increased sensitivity to sunlight (photosensitivity).

New Skin Cancers

There is an increased risk of developing new skin cancers, such as cutaneous squamous cell carcinoma and keratoacanthoma, while taking this medication. Regular skin examinations by a healthcare professional are usually performed during treatment and for several months after stopping.

High Blood Pressure

Qinlock can cause high blood pressure or worsen existing hypertension. Blood pressure levels are typically monitored closely, and medication to control blood pressure may be needed.

Heart Dysfunction

This drug may affect how well the heart pumps blood. Symptoms of heart problems can include shortness of breath, swelling in the ankles or feet, or a rapid heartbeat. Heart function tests, such as echocardiograms, may be conducted before and during treatment.

Wound Healing Complications

Treatment can impair the body's ability to heal wounds. It is generally recommended to stop taking the medication at least one week before a scheduled surgery and to wait at least two weeks after surgery before restarting, provided the wound is healing well.

Pregnancy and Reproduction

Qinlock can cause fetal harm if taken during pregnancy. Effective birth control should be used during treatment and for at least one week after the final dose. This applies to both females of reproductive potential and males with female partners of reproductive potential.

Pregnancy

Qinlock can cause fetal harm when administered to a pregnant person. Animal studies indicate that the medication may cause birth defects or pregnancy loss. It is important to inform a healthcare provider if you are pregnant or planning to become pregnant before starting this medication.

Healthcare providers typically advise the following regarding pregnancy and contraception:

• Pregnancy Testing: A pregnancy test is usually required for individuals who can become pregnant before starting treatment.
• Contraception for Females: Use effective birth control during treatment and for at least 1 week after the final dose.
• Contraception for Males: Males with female partners of reproductive potential should use effective birth control during treatment and for at least 1 week after the final dose.

Breastfeeding

It is not known whether ripretinib passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment with Qinlock and for at least 1 week after the last dose.

Fertility

Qinlock may impair fertility in both males and females of reproductive potential. This may affect the ability to father a child or become pregnant. Patients should discuss fertility concerns with their healthcare team before beginning treatment.

Dosage Forms

Qinlock is provided as a tablet for oral administration. It is intended to be swallowed whole and is taken by mouth on a daily schedule.

FDA Approval History

The U.S. Food and Drug Administration (FDA) approved Qinlock in May 2020. It was the first medication specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumors.

Approved Indications

Qinlock is indicated for the treatment of adult patients with advanced GIST who have previously been treated with three or more kinase inhibitors, including imatinib. It is used when the cancer has progressed or when other treatments are no longer effective.

Regulatory Status and Safety Monitoring

Qinlock is a prescription-only medication. At this time, the FDA does not require a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) for this drug. However, regulatory information indicates that healthcare providers must monitor patients for specific safety concerns, including:

• Skin reactions: Monitoring for hand-foot skin reaction and other dermatological issues.
• Cardiovascular health: Checking for new or worsening high blood pressure or heart failure.
• New cancers: Monitoring for the development of new skin cancers (squamous cell carcinoma or keratoacanthoma) during treatment.

Insurance and Pharmacy Factors

The price of Qinlock is largely influenced by the type of health insurance plan a patient has, including private insurance or Medicare Part D. Because it is a specialized treatment for advanced gastrointestinal stromal tumors (GIST), it is typically dispensed through specialty pharmacies rather than standard retail pharmacies. These specialty pharmacies may have different pricing structures based on insurance contracts.

Out-of-Pocket Costs

Patients may be responsible for various out-of-pocket expenses, such as deductibles, co-payments, or co-insurance. The total cost will also depend on the prescribed dosage and the duration of the treatment as determined by a healthcare provider.

Financial Assistance

Assistance programs may be available to help reduce the cost for eligible patients. These can include manufacturer-sponsored co-pay cards for those with commercial insurance or patient assistance programs for individuals who are uninsured or underinsured. Patients are encouraged to discuss these options with their medical team or a specialty pharmacy coordinator.